Prophylactic efficacy of ninjin’yoeito for oxaliplatin-induced cumulative peripheral neuropathy in patients with colorectal cancer receiving postoperative adjuvant chemotherapy: a randomized, open-label, phase 2 trial (HOPE-2)
- 30 March 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in International Journal of Clinical Oncology
- Vol. 25 (6), 1123-1129
- https://doi.org/10.1007/s10147-020-01648-3
Abstract
Purpose Peripheral neuropathy (PN) is an intractable side effect of oxaliplatin, with no effective prophylaxis so far. Ninjin’yoeito (NYT), a Kampo medicine, is protective against oxaliplatin-induced neuronal cell injury in vitro and ameliorates oxaliplatin-induced PN in vivo. Thus, this randomized controlled trial was aimed at clarifying NYT’s prophylactic effect for oxaliplatin-induced cumulative PN. Methods 52 patients with colorectal cancers of pathological stage 3 received postoperative adjuvant chemotherapy with the CapeOX regimen: eight cycles of capecitabine (2400 mg/m2) plus oxaliplatin (130 mg/m2) at 3-week intervals. They were randomly assigned to NYT administration and non-administration groups. NYT (9.0 g/day) was administered from day 1 of cycle 1 in the NYT group. The NYT was administered orally daily throughout each cycle. The primary endpoint was the grade of cumulative PN at the end of eight cycles. The secondary endpoints included relative dose intensity (RDI) of oxaliplatin, recurrence-free survival (RFS), and overall survival (OS). Results 40 patients (n = 20 in both groups) completed 8 chemotherapy cycles. The incidence of grade 2 or greater cumulative PN at the 8th chemotherapy cycle was significantly lower in the NYT group (2/20, 10.0%) than in the control group (11/20, 55.0%, P < 0.01). RDI of oxaliplatin was significantly higher in the NYT group than in the control group (P = 0.02). RFS and OS were better in the NYT group than in the control group, but the difference was not significant. Conclusions NYT may reduce the incidence of oxaliplatin-induced cumulative PN and facilitate maintenance of the CapeOX dosing regimen.Keywords
Funding Information
- Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (No. 16K09267)
This publication has 24 references indexed in Scilit:
- Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III studyInternational Journal of Clinical Oncology, 2015
- Potential Neuroprotective Activity of Ginseng in Parkinson’s Disease: A ReviewJournal of Neuroimmune Pharmacology, 2014
- Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double-blind, placebo-controlled trial of goshajinkigan to prevent oxaliplatin-induced neuropathyCancer Chemotherapy and Pharmacology, 2013
- Objective evaluation of the alleviating effects of Goshajinkigan on peripheral neuropathy induced by paclitaxel/carboplatin therapy: A multicenter collaborative studyExperimental and Therapeutic Medicine, 2011
- Traditional Japanese medicine, Kampo: Its history and current statusChinese Journal of Integrated Medicine, 2011
- The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimenInternational Journal of Clinical Oncology, 2011
- Administration of Chinpi, a Component of the Herbal Medicine Ninjin-Youei-To, Reverses Age-Induced DemyelinationEvidence-Based Complementary and Alternative Medicine, 2011
- Randomized Phase II Trials: Time for a New Era in Clinical Trial DesignJournal of Thoracic Oncology, 2010
- Restoration of FcRγ/Fyn signaling repairs central nervous system demyelinationJournal of Neuroscience Research, 2007
- Induction of histone acetylation and inhibition of growth by phenyl alkanoic acids and structurally related moleculesCancer Chemotherapy and Pharmacology, 2004